[HTML][HTML] SGLT2 inhibitors and cardiovascular outcomes in heart failure with mildly reduced and preserved ejection fraction: a systematic review and meta-analysis
Aim To provide a pooled effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on
cardiovascular outcomes in patients with heart failure with preserved ejection fraction …
cardiovascular outcomes in patients with heart failure with preserved ejection fraction …
Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis
Y Wang, T Gao, C Meng, S Li, L Bi, Y Geng… - European journal of …, 2022 - Springer
Objectives Heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with
preserved ejection fraction (HFpEF) are associated with significant morbidity and mortality …
preserved ejection fraction (HFpEF) are associated with significant morbidity and mortality …
The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
AJ Scheen - Expert Review of Endocrinology & Metabolism, 2023 - Taylor & Francis
Introduction Sodium-glucose cotransporter 2 inhibitors (SGLT2is, gliflozins), the most recent
oral antihyperglycaemic agents, provide a cardiorenal protection, an effect independent of …
oral antihyperglycaemic agents, provide a cardiorenal protection, an effect independent of …
Sodium-glucose cotransporter type 2 inhibitors and cardiac arrhythmias
AA Manolis, TA Manolis, H Melita… - Trends in Cardiovascular …, 2023 - Elsevier
The introduction of sodium-glucose cotransporter 2 (SGLT2) inhibitors as a new and
effective class of therapeutic agents for type 2 diabetes (T2D) preventing the reabsorption of …
effective class of therapeutic agents for type 2 diabetes (T2D) preventing the reabsorption of …
[HTML][HTML] SGLT2 inhibitors among patients with heart failure with preserved ejection fraction: A meta-analysis of randomised controlled trials
Background: Sodium-glucose co-transporter 2 (SGLT2) inhibitors have been recommended
in the practice guidelines for the treatment of patients with heart failure with reduced ejection …
in the practice guidelines for the treatment of patients with heart failure with reduced ejection …
[HTML][HTML] Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: a meta-analysis of randomized controlled trials
H Fukuta, H Hagiwara, T Kamiya - IJC Heart & Vasculature, 2022 - Elsevier
Background Nearly half of patients with heart failure (HF) have preserved ejection fraction
(EF) and the mortality and morbidity of patients with HF with preserved EF (HFpEF) are high …
(EF) and the mortality and morbidity of patients with HF with preserved EF (HFpEF) are high …
Comparative cardiovascular benefits of individual SGLT2 inhibitors in type 2 diabetes and heart failure: a systematic review and network meta-analysis of randomized …
T Kongmalai, P Hadnorntun… - Frontiers in …, 2023 - frontiersin.org
Background In patients with type 2 diabetes (T2D) and a history of heart failure (HF), sodium–
glucose cotransporter-2 inhibitors (SGLT2is) have demonstrated cardiovascular (CV) …
glucose cotransporter-2 inhibitors (SGLT2is) have demonstrated cardiovascular (CV) …
[PDF][PDF] NEW DIRECTIONS IN PHARMACOLOGICAL TREATMENT WITH SGLT-2 INHIBITOR MOLECULES IN THE LIGHT OF CURRENT GUIDELINES FOR …
MC Tilinca, C Antal, A SĂLCUDEAN, BL ABĂLAŞEI… - …, 2023 - farmaciajournal.com
Abstract Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, a newer class of oral anti-
hyperglycaemic agents, have been shown to improve cardiovascular and renal outcomes in …
hyperglycaemic agents, have been shown to improve cardiovascular and renal outcomes in …
SGLT-2 inhibitors for patients with heart failure: what have we learned recently?
M Al Rifai, LK Newby, AP Nair, A Misra… - Current atherosclerosis …, 2022 - Springer
Abstract Purpose of Review In this review, we discuss the mechanisms of action of sodium-
glucose cotransporter-2 inhibitors (SGLT-2i) and the purported protective effects for …
glucose cotransporter-2 inhibitors (SGLT-2i) and the purported protective effects for …
Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: An overview of 36 systematic …
The recently published randomized trials (RCTs) evaluating the effect of Sodium-glucose
cotransporter-2 inhibitors (SGLT2i) in heart failure with mildly reduced (HFmrEF) or …
cotransporter-2 inhibitors (SGLT2i) in heart failure with mildly reduced (HFmrEF) or …